Relmada halts REL-1017 Phase 3 trials after DMC review; begins strategic review

RELMADA THERAPEUTICS, INC.

Discontinues Reliance II and Relight Phase 3 studies for major depressive disorder candidate REL-1017.
Decision follows data monitoring committee evaluation of full Reliance II dataset.
Will continue advancing Phase 1 study of REL-P11, a metabolic disease investigational agent.
Commenced process to explore strategic alternatives including sale, merger, or asset acquisition.
Engaging financial advisor; no timetable set for completion of strategic review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.